

PainChek continues momentum across implementation, market and international expansion

- Increased uptick with global implemented licences
- WA Govt agreement signed to fund development of PainChek App for children with disabilities
- Royal Edinburgh Hospital, Scotland commences live integrated PainChek trial

PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitoring application, is pleased to announce a business update highlighting increased implementation and developments surrounding expansion of the technology into new markets and geographies.

Implemented licences growth

As of 30 September 2024, the Company reported a total of 100,322 contracted licences of which 61,705 had been implemented. As of 30 November 2024, total implemented licences increased to 68,136, reflecting an additional 6,431 implemented licences, a 10% increase over the past two months.

The company has continued to rollout and implement licences faster through a change in contracts and training methods. Customer contracts now include rollout schedules with implementation dates and milestone payments for larger clients across ANZ and UK. A train-the-trainer programme with UK customers also enables implementation across the larger customers. A full summary of the updated contracted and implemented beds will be provided in the December quarterly update (due end January 2025).

The company has a strong global pipeline of new clients and planned implementations to continue growth in implemented licences and ARR.

WA Govt funded agreement to develop PainChek App for non-verbal children with disabilities

Formal agreement for the Western Australian government funded development of a new PainChek App to assess pain for non-verbal children with disabilities is now in place. The project was made possible by a \$392,820 grant from the Western Australian Government’s Future Health Research and Innovation Fund, that will be used to fully fund the research and development of the new PainChek App.

The research project, known as ‘**Detecting pain in kids who can’t tell you it hurts: PainChek® for children with disabilities**’, is led by Professor Jenny Downs, Head of the Development and Disability Program and Lead of the Child Disability team at The Kids Research Institute Australia (The Kids) and Dr Katherine Langdon, Perth Children’s Hospital consultant in paediatric rehabilitation medicine. The project is a collaboration between PainChek, The Kids and Perth Children’s Hospital (PCH), who initially identified an unmet need for a pain assessment tool designed and developed specifically for children with disabilities.

PainChek will hold exclusive rights to commercialise the new PainChek app positioning the company to lead the global market in advanced, technology-driven pain assessment solutions. The project is expected to be finished and ready for commercialisation in about two years.

A full media release will be released by the collaborative partners.

This government grant availability was previously announced 5 July 2022 on the ASX.

Royal Infirmary of Edinburgh Hospital commences live integrated PainChek trial

The Royal Infirmary of Edinburgh, Scotland has commenced a live trial to use PainChek across the hospital setting. The PainChek pain assessment data integrates with the with InterSystems TrakCare health information system, following successful collaboration with InterSystems to build and test this new process. The InterSystems TrakCare is a global interoperable system used within hospitals worldwide, connecting care teams across the healthcare ecosystem and providing healthcare professionals with a single source of truth for clinical information.

The PainChek trial is planned to run for 16 weeks and used as the basis of a business case for broader roll out across the Edinburgh hospital network. Moreover, the integrated PainChek and TrakCare process is now available to access the global InterSystems and TrakCare hospital network.

PainChek CEO Philip Daffas stated:

“The Company is on track with its three focus business areas. This includes growing our core businesses in existing markets, entering new markets including specifically the USA, and market development of the large infant market where 150 million children are born each year and objective pain assessment is not currently available. In addition, the WA Government funded agreement shows we are continuing to expand our portfolio to ensure no person suffers from pain in silence. We thank our shareholders for their continued support as we continue pursuit of these opportunities.”

This release has been authorized for release by PainChek CEO Philip Daffas.

For more information:

Natalie Climo
Company Secretary, PainChek
natalie.climo@boardroomlimited.com.au
02 8016 2875

Philip Daffas
CEO, PainChek
philip.daffas@painchek.com
0406 537 235

About PainChek®

[PainChek®](#) is the world’s first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek's AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek's detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom, with FDA review in the United States currently in progress.

PainChek® has contracts with over 1,600 aged care facilities, with more than 7,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer-reviewed journals including the [Journal of Alzheimer's Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#).

PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>